Prostate Cancer: Page 4

Indica gets CE-IVD Mark for prostate cancer screening tool
By LabPulse.com staff writers
The algorithm helps pathologists identify and grade prostate cancer from core needle biopsy samples. It was developed by researchers at the University of Cologne in Germany and was trained with more than 870,000 digital scans of prostate cancer subtypes as well as healthy tissue.
May 22, 2022
2022 05 23 20 07 1373 2022 05 23 Indica Labs Halo Prostate Ai 400
Artemis signs $250M deal for liquid biopsy tests with Datar
By LabPulse.com staff writers
The contract gives Artemis DNA the exclusivity to commercialize and distribute the liquid biopsy tests Trucheck Pragma and Cancertrack in the U.S. and Vietnam. Trucheck Pragma is a noninvasive blood-based screening test for lung, stomach, colon, pancreas, prostate, breast, and ovarian cancers; Cancertrack is a cancer monitoring test that allows patients to evaluate response/resistance during treatment and monitor recurrence of cancer.
May 15, 2022
2017 09 14 23 05 1167 Cancer Cell 400
Paige gets nod in Europe for prostate biomarker suite
By LabPulse.com staff writers
The AI software is designed to detect the presence of four prostate cancer biomarkers on digitized tissue images stained with hematoxylin and eosin (H&E).
May 11, 2022
2021 08 18 23 12 2135 Computer Ai Artificial Illustration 400
Cleveland Diagnostics' IsoPSA gets NCCN prostate cancer listing
By LabPulse.com staff writers
The guidelines now suggest use of IsoPSA to categorize probability of high-grade prostate cancer (i.e., Gleason score equal to or greater than 3+4, and group grade of 2 or higher) before a first biopsy or after a negative biopsy, the company said.
May 10, 2022
2019 10 16 20 31 7121 Cancer Cells Prostate 400
Accounting for genetic factors may improve PSA testing
By LabPulse.com staff writers
Presenter Linda Kachuri, PhD, of the University of California, San Francisco, and colleagues investigated whether particular genetic factors could cause variations in PSA levels that are not due to cancer, and whether accounting for these could improve PSA testing. They conducted a study that included 95,000 men with diagnosed prostate cancer from cohorts in the U.S., the U.K., and Sweden and identified 128 PSA-associated variants they used to "build a polygenic score for PSA levels."
April 10, 2022
2019 10 16 20 31 7121 Cancer Cells Prostate 400
MiR Scientific, Leonie Hill to partner on prostate cancer test
By LabPulse.com staff writers
The test uses a single urine sample to identify prostate cancer and classify disease severity, according to miR Scientific. Its technology is based on analyzing small noncoding RNAs taken from urinary exosomes; clinical studies have shown that it can find and categorize clinically significant prostate cancer with more than 90% accuracy, the company said.
March 27, 2022
2021 01 08 22 20 9120 Cancer Cell Target2 400
Lunaphore, MGH collaborate on IVD work for solid tumors
By LabPulse.com staff writers
The collaboration will focus on ovarian, breast, and prostate cancers. The two entities will work together to develop a multiplexed immunofluorescence assay that will measure multiple protein expression.
February 17, 2022
2022 02 18 20 26 7651 2022 02 18 Lunaphore 400
Datar secures FDA breakthrough nod for prostate cancer test
By LabPulse.com staff writers
TriNetra-Prostate identifies early-stage prostate cancer in men between the ages of 55 and 69 with more than 99% accuracy, the company said. It requires 5 ml of blood and is indicated for men with a serum prostate-specific antigen (PSA) measure of 3 ng/mL or higher, according to Datar.
February 13, 2022
2019 04 22 18 53 8505 Lab Blood Liquid Samples 400
Veracyte to highlight new Decipher data at ASCO meeting
By LabPulse.com staff writers
The abstracts report results from a phase III study that evaluated the Decipher genomic classifier as a prognostic biomarker for patients diagnosed with intermediate-risk prostate cancer from diagnostic biopsy specimens, Veracyte said.
January 30, 2022
2021 11 10 18 26 8156 Science Genome Sequence Dna Map 400
Paige AI software gets U.K. medtech innovation evaluation
By LabPulse.com staff writers
MIBs are intended to support the U.K.'s National Health Service (NHS) facilities when they are considering the use of new medical devices, Paige said. This MIB is the first for a digital pathology product, according to the firm.
December 5, 2021
2019 12 13 00 30 9288 Thumbs Up Down New 400
Deep Bio, Tribun collaborate on AI-based digital pathology
By LabPulse.com staff writers
DeepDx, Deep Bio's deep learning-based prostate cancer diagnostic support software, will be integrated with CaloPix, part of the Tribun Health Platform. Using CaloPix, pathologists can now leverage automated prostate cancer image analysis using AI, Deep Bio said.
November 30, 2021
2020 03 12 20 41 0454 Computer Brain Circuit Ai 400
AI of pathology slides improves prostate cancer diagnosis
By Joseph Constance
The study suggests that AI has the potential to transform histopathological evaluation and optimize the risk stratification and clinical management of prostate cancer, giving it more of a precision approach, according to the study's authors, from the University of Wisconsin and elsewhere.
November 3, 2021
2021 04 27 15 25 5437 Pathology Digital Workstation Microscope 400
Previous Page
Page 4 of 8
Next Page